Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma

PURPOSE: Outcome measures that comprehensively capture attributes of immuno-oncology agents, including prolonged treatment-free time and persistent treatment-related adverse events (TRAEs), are needed to complement conventional survival end points. METHODS: We pooled data from the CheckMate 067 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Regan, Meredith M., Werner, Lillian, Rao, Sumati, Gupte-Singh, Komal, Hodi, F. Stephen, Kirkwood, John M., Kluger, Harriet M., Larkin, James, Postow, Michael A., Ritchings, Corey, Sznol, Mario, Tarhini, Ahmad A., Wolchok, Jedd D., Atkins, Michael B., McDermott, David F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901280/
https://www.ncbi.nlm.nih.gov/pubmed/31498030
http://dx.doi.org/10.1200/JCO.19.00345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901280/
https://www.ncbi.nlm.nih.gov/pubmed/31498030
http://dx.doi.org/10.1200/JCO.19.00345

Ejemplares similares